Payment overview · 2025
General Payments
$637.23
21 reported records · 8 companies
Healthcare provider profile · identity verified
David S Han, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GLENDALE, CA · NPI 1093755977
Verified facts
What the public records show
CMS Open Payments records show David S Han, M.D. received $637.23 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 44.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $281.74 | 44.2% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $153.96 | 24.2% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $55.26 | 8.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.45 | 8.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.93 | 4.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.42 | 4.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $25.84 | 4.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.63 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $637.23 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $281.74 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $153.96 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.45 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.65 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.68 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.68 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.68 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.93 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.42 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $25.84 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
42 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 466 | 137 |
| Losartan Potassium | Losartan Potassium | 371 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 328 | 105 |
| Metformin Hcl | Metformin Hcl | 200 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 46 |
| Tramadol Hcl | Tramadol Hcl | 150 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 42 |
| Allopurinol | Allopurinol | 116 | 32 |
| Omeprazole | Omeprazole | 115 | 40 |
| Telmisartan | Telmisartan | 113 | 36 |
| Finasteride | Finasteride | 107 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 78 | 32 |
| Lisinopril | Lisinopril | 73 | 21 |
| Carvedilol | Carvedilol | 70 | 21 |
| Gabapentin | Gabapentin | 68 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 20 |
| Jardiance | Empagliflozin | 62 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 60 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 60 | 20 |
| Trazodone Hcl | Trazodone Hcl | 60 | 17 |
| Alprazolam | Alprazolam | 53 | 14 |
| Azithromycin | Azithromycin | 52 | 43 |
| Vascepa | Icosapent Ethyl | 52 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 12 |
| Memantine Hcl | Memantine Hcl | 47 | 12 |
| Famotidine | Famotidine | 46 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 25 |
| Furosemide | Furosemide | 45 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 15 |
| Meloxicam | Meloxicam | 43 | 23 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 41 |
| Alendronate Sodium | Alendronate Sodium | 41 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | suppressed |
| Potassium Chloride | Potassium Chloride | 40 | 12 |
| Eliquis | Apixaban | 39 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 14 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Lidocaine | Lidocaine | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | 17 |
| Creon | Lipase/Protease/Amylase | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 11 |
| Hydrocortisone | Hydrocortisone | 31 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 17 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 11 |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Diazepam | Diazepam | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | 13 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $637.23 · 21 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, CREON, FREESTYLE LIBRE 3, JARDIANCE, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, VYNDAQEL, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error